Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share

IBER.WS

IBER.WS Hedge Fund Activity: Q1 2023 in Review

1 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share (IBER.WS) for Q1 2023, worth a combined $108K — down 94% from $1.78M a quarter earlier.

Sellers outnumbered buyers: 32 funds closed out of IBER.WS and 0 opened new positions — a net loss of 32 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Radcliffe Capital Management, exiting entirely with an estimated $1.51M sold.

• 1 institutional investor held Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share (IBER.WS) as of Q1 2023, down from 33 in Q4 2022.
• Funds reported $108K of Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share stock for Q1 2023, down 94% quarter-over-quarter.
• 0 funds opened new Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share positions in Q1 2023 and 32 closed out, a net change of -32 holders.
• The largest Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share seller in Q1 2023 was Radcliffe Capital Management, an estimated $1.51M sold.

Based on aggregated 13F filings for Q1 2023.